Unit sales / product sales

Negotiated / spread-based

12.9% Gross Margin (Thin (<20%))

Product sales

Direct sales force and healthcare provider relationships

Enterprise (healthcare providers and payers)

Government

Biopharmaceutical manufacturer

Collaborator/licensor

Moderate

Sublinear

International with US dominance

Very High

Low

No

Moderate

High

Moderate

No

High

9.9% Return on Assets (Excellent)

Defensive

Moderate

6.84x Total Debt / Equity (High leverage)

Low intensity; The April 2026 Section 232 proclamation imposes 100% US duties on imported patented drugs, APIs, and key starting materials (phased July 31 / September 29, 2026), landing hardest on China's dominant share of API/KSM supply — the sector's binding chokepoint.

Sublinear

High

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.25 (HIL — ~25% of characteristic roles agent-automatable)

Low intensity; commodities: active pharmaceutical ingredients / key starting materials (semi-processed chemical intermediates), petrochemical-derived medical resins (polypropylene, PVC), titanium and cobalt-chromium alloys, borosilicate pharmaceutical glass, liquid helium, stainless steel; geopolitical: The April 2026 Section 232 proclamation imposes 100% US duties on imported patented drugs, APIs, and key starting materials (phased July 31 / September 29, 2026), landing hardest on China's dominant share of API/KSM supply — the sector's binding chokepoint.

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

0000318154

AMGN

5.1% CapEx / Revenue (Moderate-CapEx)

Moderate

active_enforcement_matters,antitrust_exposure_flag,business_model_type_primary,business_model_type_secondary,capital_return_posture,channel_inventory_exposure,churn_vulnerability_index,currency_risk_exposure,customer_acquisition_metric,customer_segment_primary,customer_segment_secondary,cyber_framework_alignment,cyber_incident_materiality,cyber_oversight_body,data_sovereignty_risk,employee_headcount,franchise_compliance_risk,geographic_footprint,geopolitical_supply_exposure,headcount_cost_structure,hedging_program_scope,howey_test_risk_index,interest_rate_sensitivity,international_expansion_readiness,key_person_dependency,liquidity_sufficiency_assertion,marginal_cost_of_growth,market_structure,monetization_vector,named_competitors,network_effect_present,pricing_architecture,pricing_power_rating,product_revenue_concentration,purchase_commitment_rigidity,recession_resistance_tier,regulatory_burden_tier,revenue_model_type,seasonality_pattern,supply_chain_dependency,switching_cost_profile,trade_restriction_exposure,vendor_lock_dependency_score

0

7

-11349

2026-08-13

2026-10-03T13:43|activist_13d_count_1y,activist_last_13d_date,blockholder_13g_count_1y,insider_buys_6m,insider_last_transaction_date,insider_net_shares_6m,insider_sells_6m

31,500; ~41% outside U.S.

Low

Novartis AG, Regeneron Pharmaceuticals Inc., Sanofi, AbbVie Inc., Eli Lilly and Company, Johnson & Johnson, Bristol Myers Squibb Company, Pfizer Inc., AstraZene

Fragmented

Prolia = 12.6% of revenue; Repatha = 8.6%; Otezla = 6.4%; no single segment >30%

Dividend+Buyback; FY2025: $1.8B dividends (approximately), $0 buybacks; FY2024: $200M buybacks

Moderate; tariffs; no dollar amount quantified

Mild; Q1 weakness from plan changes and deductibles

Affirmed

Moderate-High; three wholesalers represent 77% of gross revenues

Yes; IRS transfer pricing disputes; U.S. Tax Court

Low; no material disclosed non-cancellable commitments

No

Not named; generic industry frameworks referenced

Corporate Responsibility and Compliance Committee (CRCC) with Board oversight

Moderate; predominantly euro; ~27% of revenue from ROW

FX forwards on euro revenue (~$7.8B notional); cross-currency swaps on euro/pound-denominated debt (~$2.7B notional); interest rate swaps on fixed-rate debt (~$

0

3

none in window

Unit sales / product sales

Negotiated / spread-based

12.9% Gross Margin (Thin (<20%))

Product sales

Direct sales force and healthcare provider relationships

Enterprise (healthcare providers and payers)

Government

Biopharmaceutical manufacturer

Collaborator/licensor

Moderate

Sublinear

International with US dominance

Very High

Low

No

Moderate

High

Moderate

No

High

9.9% Return on Assets (Excellent)

Defensive

Moderate

6.84x Total Debt / Equity (High leverage)

Low intensity; The April 2026 Section 232 proclamation imposes 100% US duties on imported patented drugs, APIs, and key starting materials (phased July 31 / September 29, 2026), landing hardest on China's dominant share of API/KSM supply — the sector's binding chokepoint.

Sublinear

High

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.25 (HIL — ~25% of characteristic roles agent-automatable)

Low intensity; commodities: active pharmaceutical ingredients / key starting materials (semi-processed chemical intermediates), petrochemical-derived medical resins (polypropylene, PVC), titanium and cobalt-chromium alloys, borosilicate pharmaceutical glass, liquid helium, stainless steel; geopolitical: The April 2026 Section 232 proclamation imposes 100% US duties on imported patented drugs, APIs, and key starting materials (phased July 31 / September 29, 2026), landing hardest on China's dominant share of API/KSM supply — the sector's binding chokepoint.

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

0000318154

AMGN

5.1% CapEx / Revenue (Moderate-CapEx)

Moderate

active_enforcement_matters,antitrust_exposure_flag,business_model_type_primary,business_model_type_secondary,capital_return_posture,channel_inventory_exposure,churn_vulnerability_index,currency_risk_exposure,customer_acquisition_metric,customer_segment_primary,customer_segment_secondary,cyber_framework_alignment,cyber_incident_materiality,cyber_oversight_body,data_sovereignty_risk,employee_headcount,franchise_compliance_risk,geographic_footprint,geopolitical_supply_exposure,headcount_cost_structure,hedging_program_scope,howey_test_risk_index,interest_rate_sensitivity,international_expansion_readiness,key_person_dependency,liquidity_sufficiency_assertion,marginal_cost_of_growth,market_structure,monetization_vector,named_competitors,network_effect_present,pricing_architecture,pricing_power_rating,product_revenue_concentration,purchase_commitment_rigidity,recession_resistance_tier,regulatory_burden_tier,revenue_model_type,seasonality_pattern,supply_chain_dependency,switching_cost_profile,trade_restriction_exposure,vendor_lock_dependency_score

0

7

-11349

2026-08-13

2026-10-03T13:43|activist_13d_count_1y,activist_last_13d_date,blockholder_13g_count_1y,insider_buys_6m,insider_last_transaction_date,insider_net_shares_6m,insider_sells_6m

31,500; ~41% outside U.S.

Low

Novartis AG, Regeneron Pharmaceuticals Inc., Sanofi, AbbVie Inc., Eli Lilly and Company, Johnson & Johnson, Bristol Myers Squibb Company, Pfizer Inc., AstraZene

Fragmented

Prolia = 12.6% of revenue; Repatha = 8.6%; Otezla = 6.4%; no single segment >30%

Dividend+Buyback; FY2025: $1.8B dividends (approximately), $0 buybacks; FY2024: $200M buybacks

Moderate; tariffs; no dollar amount quantified

Mild; Q1 weakness from plan changes and deductibles

Affirmed

Moderate-High; three wholesalers represent 77% of gross revenues

Yes; IRS transfer pricing disputes; U.S. Tax Court

Low; no material disclosed non-cancellable commitments

No

Not named; generic industry frameworks referenced

Corporate Responsibility and Compliance Committee (CRCC) with Board oversight

Moderate; predominantly euro; ~27% of revenue from ROW

FX forwards on euro revenue (~$7.8B notional); cross-currency swaps on euro/pound-denominated debt (~$2.7B notional); interest rate swaps on fixed-rate debt (~$

0

3

none in window